{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:18:44Z","timestamp":1789683524739,"version":"4.0.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.obpill.2026.100248","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:13:46Z","timestamp":1769156026000},"page":"100248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials"],"prefix":"10.1016","volume":"17","author":[{"given":"Jaime P.","family":"Almandoz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavia","family":"Pickett-Blakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Tewksbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Stefanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Gonsahn-Bollie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6662-804X","authenticated-orcid":false,"given":"Georgios K.","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada Leticia","family":"Murro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dachuang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qier","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-6057","authenticated-orcid":false,"given":"Lisa M.","family":"Neff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.obpill.2026.100248_bib1","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/oby.24067","article-title":"Nutritional considerations with antiobesity medications","volume":"32","author":"Almandoz","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.obpill.2026.100248_bib2","article-title":"Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study","volume":"15","author":"Butsch","year":"2025","journal-title":"Obes Pillars"},{"issue":"6","key":"10.1016\/j.obpill.2026.100248_bib3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/oby.24027","article-title":"Physiology of the weight loss plateau after calorie restriction, GLP-1 receptor agonism, and bariatric surgery","volume":"32","author":"Hall","year":"2024","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"10.1016\/j.obpill.2026.100248_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"SURMOUNT-1 investigators. Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10402","key":"10.1016\/j.obpill.2026.100248_bib5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.obpill.2026.100248_bib6","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.obpill.2026.100248_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"SURMOUNT-4 investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.obpill.2026.100248_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000471","article-title":"Impact of malnutrition on survival and healthcare utilization in medicare beneficiaries with diabetes: a retrospective cohort analysis","volume":"6","author":"Ahmed","year":"2018","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"10.1016\/j.obpill.2026.100248_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/0148607112440285","article-title":"Consensus statement: Academy of nutrition and dietetics and American society for parenteral and enteral nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition)","volume":"36","author":"White","year":"2012","journal-title":"JPEN - J Parenter Enter Nutr"},{"issue":"1","key":"10.1016\/j.obpill.2026.100248_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clnu.2016.09.004","article-title":"ESPEN guidelines on definitions and terminology of clinical nutrition","volume":"36","author":"Cederholm","year":"2017","journal-title":"Clin Nutr"},{"issue":"4","key":"10.1016\/j.obpill.2026.100248_bib11","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ajcn\/68.4.899","article-title":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary","volume":"68","year":"1998","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.obpill.2026.100248_bib13","series-title":"Physical status: the use of and interpretation of anthropometry. Report of a WHO expert committee","year":"1995"},{"issue":"1","key":"10.1016\/j.obpill.2026.100248_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jpen.1440","article-title":"GLIM criteria for the diagnosis of malnutrition: a consensus report from the global clinical nutrition community","volume":"43","author":"Jensen","year":"2019","journal-title":"JPEN - J Parenter Enter Nutr"},{"issue":"1","key":"10.1016\/j.obpill.2026.100248_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ncp.10588","article-title":"The use of visceral proteins as nutrition markers: an ASPEN position paper","volume":"36","author":"Evans","year":"2021","journal-title":"Nutr Clin Pract"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:42:31Z","timestamp":1773985351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368126000045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":14,"alternative-id":["S2667368126000045"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100248","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Eli Lilly and Company. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100248"}}